Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 16/20 | 0.60 |
| ▸ | GIPR | P48546 | 14/20 | 0.60 |
| ▸ | GLP1R | P43220 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 2/20 | 0.38 |
| ▸ | STAT1 | P42224 | 1/20 | 0.38 |
| ▸ | STAT5B | P51692 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2665445 | 0.89 | GCGR (0.55) | GCGRGIPRGLP1ROPRM1OPRK1 | |
| SCHEMBL2655183 | 0.88 | GCGR (0.71) | GCGRGIPRGLP1RBCL2L1MCL1 | |
| SCHEMBL2655185 | 0.88 | GCGR (0.71) | GCGRGIPRGLP1RBCL2L1MCL1 | |
| SCHEMBL2665444 | 0.86 | GCGR (0.60) | GCGRGIPRGLP1R | |
| SCHEMBL2665448 | 0.85 | GCGR (0.62) | GCGRGIPRGLP1ROPRM1OPRK1 | |
| SCHEMBL2665443 | 0.85 | GCGR (0.78) | GCGRGIPRGLP1R | |
| SCHEMBL9070845 | 0.84 | GCGR (0.60) | GCGRGIPRGLP1ROPRM1OPRK1 | |
| SCHEMBL9071073 | 0.82 | GCGR (0.58) | GCGRGIPRGLP1R | |
| SCHEMBL2646282 | 0.81 | GCGR (0.60) | GCGRGIPRGLP1RSTAT3 | |
| SCHEMBL2646285 | 0.81 | GCGR (0.60) | GCGRGIPRGLP1RSTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003051357-A1 | GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |